埃索美拉唑和奥美拉唑治疗幽门螺旋杆菌的成本-效果分析  

The cost-effectiveness analysis of Helicobacter pylori treatment between esomeprazole and omeprazole

作　　者：胡玥珊[1] 姜明燕[1] 

机构地区：[1]中国医科大学附属第一医院,辽宁沈阳110001

出　　处：《中国医院药学杂志》2014年第21期1855-1857,1880,共4页Chinese Journal of Hospital Pharmacy

基　　金："十二五"国家科技支撑计划2013年项目"安全合理用药评价和干预技术研究与应用"(课题编号:2013BAI06B04)

摘　　要：目的:比较埃索美拉唑与奥美拉唑治疗由幽门螺旋杆菌(Helicobacter pylori,Hp)引起的消化性溃疡的疗效与用药费用。方法:通过查阅Pubmed、Medline、Cochrane、Embase数据库,搜索埃索美拉唑治疗消化性溃疡的RCT文献共4篇,其中消化性溃疡患者1 599例随机分为埃索美拉唑组(EAC组)和奥美拉唑组(OAC组)。EAC组给予埃索美拉唑20 mg,OAC组给予奥美拉唑钠20 mg,两组方案给药方式均为bid,口服,疗程4周;两组均加抗生素联合治疗。运用药物经济学原理对两种治疗方案进行成本-效果分析。结果:EAC组与OAC组成本(C)分别为903.35元、884.9元,Hp根除率分别为84.16%、84.32%(P>0.05),其成本-效果比(C/E)分别为1 073.37、1 049.45;EAC组相对于OAC组治疗Hp根除率的增量成本-效果比(ΔC/ΔE)为11 531.25。结论:两组方案治疗效果相当,奥美拉唑组治疗消化性溃疡的效价比较高,其药物经济学价值也更高。OBJECTIVE To compare the efficacy and costs of esomeprazole group （EAC） vs omeprazole group（OAC） treating peptic ulcer caused by Helicobacter pylori. METHODS 4 RCT articles that esomeprazole treated peptic ulcer were searched through the Pubmed, Medline, Cochrane and Embase database, including 1 599 peptic ulcer patients who were divided into EAC group or OAC group randomly. EAC group patients were given esomeprazole 20 mg, bid. , p.o. 4 weeks, OAC group given omeprazole 20 mg, bid. , p.o. 4 weeks. Two groups were all given in combination with antibiotic. RESULTS The costs of esomeprazole group and omeprazole group were 859. 35 Yuan, 794. 37 Yuan, respectively. Hp eradication rates were 84. 16% （EAC）, 84. 32% （OAC） （P：〉0. 05）. Cost-effectiveness ratio （C/E） of Hp eradication were 1073.37,1 049. 45, respectively. The incremental cost-effectiveness ratio （AC/AE） of EAC relative to OAC was 11 531.25 for Hp eradication. CONCLUSION The effects of two groups were equal, but the effective value and pharmacoeconomics＇ value of OAC group were higher.

关 键 词：埃索美拉唑 奥美拉唑 幽门螺旋杆菌 成本-效果分析 

分 类 号：R956[医药卫生—药学]